There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
5 responses
4,083 views
0 reactions
|
11-01-2010, 02:27 PM
|
|||
|
6 responses
7,235 views
0 reactions
|
by shurjo
10-30-2010, 09:58 PM
|
|||
|
0 responses
3,531 views
0 reactions
|
by pie
10-29-2010, 08:41 AM
|
|||
|
0 responses
2,363 views
0 reactions
|
by lcwu
10-13-2010, 09:51 AM
|
|||
|
3 responses
2,461 views
0 reactions
|
by ychang
10-12-2010, 05:01 PM
|
|||
|
19 responses
22,530 views
0 reactions
|
by saikumarkv
10-12-2010, 08:11 AM
|
|||
|
0 responses
8,369 views
0 reactions
|
by Bjorn
10-09-2010, 02:36 PM
|
|||
|
1 response
3,173 views
0 reactions
|
by angelawu
10-08-2010, 10:51 AM
|
|||
|
0 responses
1,593 views
0 reactions
|
by NaMar
10-05-2010, 02:19 AM
|
|||
|
7 responses
5,966 views
0 reactions
|
by josdegraaf
10-04-2010, 01:08 AM
|
No topics found.
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has... -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM